BRUIN CLL-313 showed significantly longer progression-free survival vs bendamustine plus rituximab, bringing a noncovalent BTK inhibitor to first-line care.
|Articles|October 15, 2009
- October 2009
- Volume 75
- Issue 10
DIABETES PRODUCTS
Advertisement
Articles in this issue
almost 17 years ago
Case Studiesalmost 17 years ago
Health Systems Product Newsalmost 17 years ago
Women's Health Watchalmost 17 years ago
Rx Product News Profile: A closer look at new FDA actions: Multaqalmost 17 years ago
Cholesterol Watchalmost 17 years ago
Biosimilars and Health Care Reformalmost 17 years ago
Gestational Diabetes: What Patients Need to Knowalmost 17 years ago
Blood Glucose Monitors for the Pediatric Populationalmost 17 years ago
2-Minute Consultation: Preventive Foot Care for Diabetes Patientsalmost 17 years ago
GERD WatchAdvertisement
Related to this article
A behavioral walking program matched supervised aerobic training for improving asthma control in a randomized trial of physically inactive adults.
Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1c by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
American Pharmacists Month kicked off on October 1, honoring more than 700,000 pharmacy professionals and 250 years of caring for America's communities.
fMRI data show cagrilintide-semaglutide altered brain responses to high-calorie food cues; REIMAGINE analyses point to ectopic fat and bone effects.
Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.
A pharmacist-led collaborative drug therapy management program at NYC Health + Hospitals/Bellevue reported high patient satisfaction, and every surveyed patient said they felt respected and supported by their pharmacist.
A Novo Nordisk–funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, although the findings cannot show causation.
Advertisement
Advertisement
Trending on Pharmacy Times
1
EloraTZP Delivers Up to 23.3% Weight Loss in Adults With Obesity and T2D
2
Pharmacists Key to Lp(a) Counseling and Lipid Optimization
3
Why Lp(a) Testing Lagged Behind LDL Cholesterol Screening
4
What the 2025-2030 Dietary Guidelines Mean for Heart Health
5